Skip to main content

Table 3 Diagnostic performance of SUV70 measurements regarding nodal recurrence within 12 months after CCRT

From: Dual time point imaging in locally advanced head and neck cancer to assess residual nodal disease after chemoradiotherapy

 

AUROC (95% CI)

TN

FN

TP

FP

Sensitivity (95% CI)

Specificity (95% CI)

PPV (95% CI)

NPV (95% CI)

P

All patients (n = 102)

SUV1 (≥ 2.2)

0.74 (0.59–0.88)

70

5

10

17

66.7% (38.4–88.2%)

80.5% (70.6–88.2%)

37.0% (25.2–50.7%)

93.3% (87.2–96.7%)

 

SUV2 (≥ 2.2)

0.76 (0.62–0.90)

69

4

11

18

73.3% (44.9–92.2%)

79.3% (69.3–87.3%)

37.9% (26.8–50.5%)

94.4% (87.8–97.5%)

0.58

SUV1 + RI (≥ 3%)

0.75 (0.60–0.91)

79

6

9

8

60.0% (32.3–83.7%)

90.8% (82.7–96.0%)

52.9% (34.1–71.0%)

92.9% (87.6–96.1%)

0.62

Equivocal (n = 24)

SUV1 (≥ 2.2)

0.67 (0.39–0.89)

9

1

5

9

83.3% (35.9–99.6%)

50.0% (26.0–74.0%)

22.3% (13.8–34.0%)

94.6% (73.3–99.1%)

 

SUV2 (≥ 2.2)

0.78 (0.56–0.94)

10

0

6

8

100% (54.1–100%)

55.6% (30.8–78.5%)

27.9% (18.8–39.4%)

100%(65.5–100%)

0.29

SUV1 + RI (≥ 3%)

0.72 (0.47–0.97)

14

2

4

4

66.7% (22.3–95.7%)

77.8% (52.4–96.6%)

34.1% (15.5–59.2%)

93.1% (81.0–97.7%)

0.58

HPV-negative OPSCC (n = 21)

SUV1 (≥ 2.2)

0.82 (0.60–1)

12

1

5

3

83.3% (35.9–99.6%)

80.0% (51.9–95.7%)

41.8% (19.7–67.8%)

96.5% (82.1–99.4%)

 

SUV2 (≥ 2.2)

0.88 (0.69–1)

14

1

5

1

83.3% (35.9–99.6%)

93.3% (68.1–99.8%)

68.3% (23.9–93.7%)

97.0% (84.4–99.5%)

0.14

SUV1 + RI (≥ 3%)

0.88 (0.69–1)

14

1

5

1

83.3% (35.9–99.6%)

93.3% (68.1–99.8%)

68.3% (23.9–93.7%)

97.0% (84.4–99.5%)

0.14

HPV-associated OPSCC (n = 32)

SUV1 (≥ 2.2)

0.56 (0.20–0.93)

23

2

1

6

33.3% (0.8–90.6%)

79.3% (60.3–92.0%)

21.7% (4.6–61.6%)

87.4% (75.2–94.0%)

 

SUV2 (≥ 2.2)

0.75 (0.42–1)

24

1

2

5

66.7% (9.4–99.2%)

82.8% (64.2–94.2%)

40.0% (17.7–67.3%)

93.5% (74.3–98.6%)

0.29

SUV1 + RI (≥ 3%)

0.47 (0.14–0.80)

27

3

0

2

0.0% (0.0–70.8%)

93.1% (77.2–99.2%)

0.0%(0.0–80.2%)

84.4% (83.0–85.6%)

0.57

  1. P comparison of AUROC values versus the SUV1 metric